JP2018517410A5 - - Google Patents

Download PDF

Info

Publication number
JP2018517410A5
JP2018517410A5 JP2017562027A JP2017562027A JP2018517410A5 JP 2018517410 A5 JP2018517410 A5 JP 2018517410A5 JP 2017562027 A JP2017562027 A JP 2017562027A JP 2017562027 A JP2017562027 A JP 2017562027A JP 2018517410 A5 JP2018517410 A5 JP 2018517410A5
Authority
JP
Japan
Prior art keywords
item
domain
nucleic acid
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017562027A
Other languages
English (en)
Japanese (ja)
Other versions
JP6833727B2 (ja
JP2018517410A (ja
Filing date
Publication date
Priority claimed from GBGB1509413.9A external-priority patent/GB201509413D0/en
Application filed filed Critical
Publication of JP2018517410A publication Critical patent/JP2018517410A/ja
Publication of JP2018517410A5 publication Critical patent/JP2018517410A5/ja
Application granted granted Critical
Publication of JP6833727B2 publication Critical patent/JP6833727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017562027A 2015-06-01 2016-05-31 細胞 Active JP6833727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1509413.9 2015-06-01
GBGB1509413.9A GB201509413D0 (en) 2015-06-01 2015-06-01 Fusion protein
PCT/GB2016/051576 WO2016193696A1 (en) 2015-06-01 2016-05-31 Cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020086590A Division JP2020115898A (ja) 2015-06-01 2020-05-18 細胞

Publications (3)

Publication Number Publication Date
JP2018517410A JP2018517410A (ja) 2018-07-05
JP2018517410A5 true JP2018517410A5 (enExample) 2019-05-09
JP6833727B2 JP6833727B2 (ja) 2021-02-24

Family

ID=53677545

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017562027A Active JP6833727B2 (ja) 2015-06-01 2016-05-31 細胞
JP2020086590A Withdrawn JP2020115898A (ja) 2015-06-01 2020-05-18 細胞
JP2022032551A Withdrawn JP2022066380A (ja) 2015-06-01 2022-03-03 細胞
JP2024137629A Pending JP2024149818A (ja) 2015-06-01 2024-08-19 細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020086590A Withdrawn JP2020115898A (ja) 2015-06-01 2020-05-18 細胞
JP2022032551A Withdrawn JP2022066380A (ja) 2015-06-01 2022-03-03 細胞
JP2024137629A Pending JP2024149818A (ja) 2015-06-01 2024-08-19 細胞

Country Status (20)

Country Link
US (2) US11345734B2 (enExample)
EP (2) EP3303568B1 (enExample)
JP (4) JP6833727B2 (enExample)
KR (1) KR102275460B1 (enExample)
CN (1) CN107667170B (enExample)
AU (1) AU2016272457B2 (enExample)
BR (1) BR112017023190A2 (enExample)
CA (1) CA2986956C (enExample)
CL (1) CL2017003057A1 (enExample)
DK (1) DK3303568T3 (enExample)
ES (1) ES2791338T3 (enExample)
GB (1) GB201509413D0 (enExample)
HU (1) HUE050132T2 (enExample)
IL (1) IL255594B (enExample)
MX (1) MX383118B (enExample)
PL (1) PL3303568T3 (enExample)
PT (1) PT3303568T (enExample)
RU (1) RU2729158C2 (enExample)
WO (1) WO2016193696A1 (enExample)
ZA (1) ZA201707334B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN108025024B (zh) 2015-07-28 2022-11-29 宾夕法尼亚大学董事会 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途
MX2018008345A (es) * 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia.
IL304088A (en) * 2016-01-11 2023-08-01 Univ Leland Stanford Junior Systems containing chimeric proteins and their uses for controlling gene expression
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201621889D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Cell
WO2018157000A1 (en) * 2017-02-23 2018-08-30 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity
US20200048359A1 (en) * 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
JP7132249B2 (ja) * 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
TWI731268B (zh) * 2017-09-29 2021-06-21 財團法人國家衛生研究院 可增強抗腫瘤與抗病毒ｔ細胞存活與其功能性之方法與組合物
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
WO2019118518A2 (en) * 2017-12-11 2019-06-20 Senti Biosciences, Inc. Inducible cell receptors for cell-based therapeutics
WO2019243817A1 (en) * 2018-06-19 2019-12-26 Autolus Limited Cell
CN109294982B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rff2细胞
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
EP3891286A4 (en) * 2018-12-06 2022-10-19 The Board of Trustees of the Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
US20220133791A1 (en) 2019-01-23 2022-05-05 Miltenyi Biotec B.V. & Co. KG A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
WO2020190771A1 (en) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
JP2022531461A (ja) * 2019-05-07 2022-07-06 モデルナティエックス インコーポレイテッド 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法
CN112279922B (zh) * 2019-07-22 2023-07-28 南京助天中科科技发展有限公司 一种吞噬细胞嵌合抗原受体及其应用
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
EP4031583A4 (en) * 2019-09-16 2023-11-15 Fred Hutchinson Cancer Center CHIMERIC RECEPTOR PROTEINS AND THEIR USES
ES2991652T3 (es) * 2019-10-23 2024-12-04 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Polipéptido quimérico para regular las células inmunitarias
WO2021096868A1 (en) * 2019-11-12 2021-05-20 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
CN115066249A (zh) 2020-02-04 2022-09-16 美天施生物科技有限两合公司 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
KR20230042691A (ko) 2020-06-04 2023-03-29 카리스마 테라퓨틱스 인코포레이티드 키메라 항원 수용체에 대한 신규한 작제물
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
US20250019740A1 (en) * 2020-10-26 2025-01-16 Board Of Regents, The University Of Texas System Mutant proteases and uses thereof
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
EP4240404A1 (en) 2020-11-09 2023-09-13 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
CN118703444A (zh) * 2021-01-22 2024-09-27 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
JP2023008482A (ja) 2021-07-06 2023-01-19 日本たばこ産業株式会社 たばこ製品の香味料担持構成部材及びこの製造方法
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
EP4426341A4 (en) * 2021-11-04 2025-10-01 Dana Farber Cancer Inst Inc DEVELOPMENT OF INDUCIBLE CHIMERIC CLUSTERED ANTIGEN RECEPTOR (CCAR) CONSTRUCTS
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN119331105B (zh) * 2024-09-03 2025-10-28 中国人民解放军空军军医大学 靶向多种免疫检查点的通用多肽-protac及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
WO1996040199A1 (en) * 1995-06-07 1996-12-19 University Of Pennsylvania Methods of inhibiting phagocytosis
US6303319B1 (en) * 1996-02-23 2001-10-16 Ariad Pharmaceuticals, Inc. Cell based assay for identifying sh2-domain-specific signal transducer antagonist
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
JP6857028B2 (ja) * 2013-03-15 2021-04-14 メモリアル スローン ケタリング キャンサー センター 免疫治療のための組成物および方法
MX377283B (es) * 2013-11-21 2025-03-07 Ucl Business Ltd Célula t o nk que coexpresa un receptor antigénico quimérico (car).
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler
GB201620070D0 (en) 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method

Similar Documents

Publication Publication Date Title
RU2017145074A (ru) Клетка
EP3749338B1 (en) Humanized bcma antibody and bcma-car-t cells
Shiratori et al. Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor
CA3132375A1 (en) Prostate-specific membrane antigen cars and methods of use thereof
JP2016538855A5 (enExample)
CN114746438A (zh) 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂
JP2016538854A5 (enExample)
JP2018523484A5 (enExample)
WO2018193231A1 (en) Cell
JP7602803B2 (ja) Ｃｄ１４７キメラ抗原受容体および使用の方法
WO2020190771A1 (en) Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
JP7728477B2 (ja) 抗ｒｏｒ１抗体及びｒｏｒ１を標的とする操作された細胞
JP6842688B2 (ja) キメラ抗原受容体
WO2025134168A1 (en) Genetically modified immune cells for the treatment of tumors and autoimmune diseases
WO2025016450A1 (en) Combination of cldn18.2 and gucy2c targeted antagonist therapy
CN119301257A (zh) 用于工程化改造固有样淋巴细胞的方法
HK40075954A (en) Disrupting tumor tissues by targeting fibroblast activation protein (fap)
GB2569692A (en) T cell antigen receptor chimera
BR122025000772A2 (pt) Célula
NZ737662B2 (en) Cell